<!doctype html>
<html lang="it">
<head>
  <meta charset="utf-8">
  <meta name="viewport" content="width=device-width, initial-scale=1">
  <title>Rassegna Ponatinib / Asciminib CML</title>
  <style>
    body {
      font-family: Arial, sans-serif;
      line-height: 1.5;
      margin: 24px auto;
      max-width: 900px;
      padding: 0 16px;
      color: #222;
      background: #fff;
    }
    h1, h2, h3 { line-height: 1.2; }
    h1 { border-bottom: 2px solid #ddd; padding-bottom: 8px; }
    h2 { margin-top: 28px; border-bottom: 1px solid #eee; padding-bottom: 4px; }
    h3 { margin-top: 22px; }
    ul { margin-top: 6px; margin-bottom: 10px; }
    li { margin-bottom: 6px; }
    hr { margin: 22px 0; border: none; border-top: 1px solid #ddd; }
    a { color: #0b57d0; text-decoration: none; }
    a:hover { text-decoration: underline; }
    p { margin: 8px 0; }
  </style>
</head>
<body>
<h1>Ponatinib / Asciminib nella LMC – Report strategico quindicinale (ultimi 30 giorni)</h1>
<p>_Generata il: 2026-03-01_</p>
<p></p>
<h2>Executive brief</h2>
<p></p>
<p><b>3 takeaway (cosa conta davvero):</b></p>
<ul>
<li>Nel periodo emergono soprattutto temi su <b>Altro</b> (n=2).</li>
<li>Secondo filone: <b>Resistenza / T315I / mutazioni</b> (n=2).</li>
<li>Terzo filone: <b>Safety e comorbidità</b> (n=1).</li>
</ul>
<p></p>
<p><b>Watchlist (cosa tenere d’occhio):</b></p>
<ul>
<li>Monitorare evoluzione su <b>Safety e comorbidità</b> (nuovi segnali/dati).</li>
<li>Monitorare evoluzione su <b>Resistenza / T315I / mutazioni</b> (nuovi segnali/dati).</li>
</ul>
<p></p>
<p><b>Action list (cosa fare in pratica):</b></p>
<ul>
<li>Rivedere/rafforzare <b>monitoraggio cardiovascolare e interazioni</b> (es. anticoagulanti) nei pazienti in TKI.</li>
<li>Valutare criteri interni per <b>consolidamento / de-escalation / TFR</b> nei pazienti in deep response.</li>
<li>Verificare percorso di <b>test mutazionale</b> e criteri di switch nelle resistenze (incl. T315I).</li>
</ul>
<p></p>
<hr>
<p></p>
<h2>Top 5 da leggere subito (ordinati per impatto)</h2>
<p></p>
<h3>1) Is asciminib an effective tyrosine kinase inhibitor for chronic myeloid leukemia patients with tyrosine kinase inhibitor resistance?</h3>
<ul>
<li><b>Impact score</b>: 12 | <b>Tipo</b>: Trial clinico</li>
<li><b>Focus clinico</b>: Resistenza / T315I / mutazioni, Safety e comorbidità</li>
<li>PMID: 41724089 | 10.1016/j.htct.2026.106257</li>
<li>Link PubMed: <a href="https://pubmed.ncbi.nlm.nih.gov/41724089/" target="_blank">https://pubmed.ncbi.nlm.nih.gov/41724089/</a></li>
</ul>
<p></p>
<ul>
<li>Tipo di studio/popolazione: Such a selective inhibitor offers an alternative treatment strategy for patients with chronic myeloid leukemia who have developed resistance to previous tyrosine kinase inhibitor therapies.</li>
<li>Risultato chiave: Although asciminib demonstrates a superior safety profile, primarily characterized by a reduction in cardiovascular adverse events associated with prior tyrosine kinase inhibitors, its clinical significance extends further.</li>
<li>Rilevanza clinica: It remains essential to continue research and clinical trials to enhance the therapeutic efficacy of asciminib and manage its associated side effects.</li>
</ul>
<p></p>
<hr>
<p></p>
<h3>2) Dual Proteasome and Histone Deacetylase Inhibition Overcomes Tyrosine Kinase Inhibitor Resistance in Breakpoint Cluster Region: Abelson 1-Driven Leukaemia Cell Lines.</h3>
<ul>
<li><b>Impact score</b>: 5 | <b>Tipo</b>: Preclinico / laboratorio</li>
<li><b>Focus clinico</b>: Resistenza / T315I / mutazioni, Dose strategy / consolidamento</li>
<li>PMID: 41696976 | 10.1111/jcmm.71053</li>
<li>Link PubMed: <a href="https://pubmed.ncbi.nlm.nih.gov/41696976/" target="_blank">https://pubmed.ncbi.nlm.nih.gov/41696976/</a></li>
</ul>
<p></p>
<ul>
<li>Tipo di studio/popolazione: Resistance to tyrosine kinase inhibitors (TKIs) remains a major challenge in breakpoint cluster region (BCR)::Abelson 1 (ABL1)-driven leukaemias.</li>
<li>Risultato chiave: Viability, cytotoxicity, and caspase-3/7 activity were assessed following single-agent treatment with asciminib, ponatinib, bortezomib, or panobinostat.</li>
<li>Rilevanza clinica: Asciminib showed reduced potency in resistant models and a right-shifted dose-response curve in T315I cells, whereas ponatinib retained activity across BCR::ABL1 variants.</li>
</ul>
<p></p>
<hr>
<p></p>
<h3>3) The Care and Cure of the Leukemias in 2026.</h3>
<ul>
<li><b>Impact score</b>: 1 | <b>Tipo</b>: Preclinico / laboratorio</li>
<li><b>Focus clinico</b>: Altro</li>
<li>PMID: 41761287 | 10.1002/ajh.70247</li>
<li>Link PubMed: <a href="https://pubmed.ncbi.nlm.nih.gov/41761287/" target="_blank">https://pubmed.ncbi.nlm.nih.gov/41761287/</a></li>
</ul>
<p></p>
<ul>
<li>Tipo di studio/popolazione: Currently, most leukemias are effectively treated with immunotherapies (highly effective monoclonal antibodies targeting CD19 [blinatumomab], or CD22 [inotuzumab ozogamicin]), BCR::ABL1 tyrosine kinase inhibitors (TKIs; e.g., dasatinib, ponatinib), Bruton TKIs (e.g., ibrutinib, acalabrutinib), BCL-2 inhibitors (venetoclax), IDH1/2 inhibitors (ivosidenib, olutasidenib, and enasidenib), FLT3 inhibitors (e.g., midostaurin, quizartinib, and gilteritinib), menin inhibitors (revumenib, ziftomenib), and chimeric antigen receptor T-cell therapies.</li>
<li>Risultato chiave: The BCR::ABL1 TKIs resulted in normal life expectancy in chronic myeloid leukemia.</li>
<li>Rilevanza clinica: Notable advances have also been made in AML with targeted therapies, although some subsets (older/unfit patients for intensive chemotherapy, complex karyotype, TP53-mutated, KMT2A-rearranged, and treated secondary AML) still have unfavorable outcomes.</li>
</ul>
<p></p>
<hr>
<p></p>
<h3>4) Secondary Chronic Myeloid Leukemia in the Blast Phase With Mixed Phenotype After Radiation Therapy: A Case Report.</h3>
<ul>
<li><b>Impact score</b>: 1 | <b>Tipo</b>: Preclinico / laboratorio</li>
<li><b>Focus clinico</b>: Altro</li>
<li>PMID: 41737783 | 10.1002/jha2.70249</li>
<li>Link PubMed: <a href="https://pubmed.ncbi.nlm.nih.gov/41737783/" target="_blank">https://pubmed.ncbi.nlm.nih.gov/41737783/</a></li>
</ul>
<p></p>
<ul>
<li>Tipo di studio/popolazione: A 55-year-old woman underwent hysterectomy and pelvic radiation for cervical cancer, which remains in remission.</li>
<li>Risultato chiave: Following induction therapy, sequential therapy with blinatumomab and ponatinib achieved qualitatively PCR-negative minor &lt;i&gt;BCR::ABL1&lt;/i&gt; transcripts, indicating that residual transcripts below the qualitative assay&#x27;s detection limit were undetectable.</li>
<li>Rilevanza clinica: She received an allogeneic bone marrow transplant and remains well with PCR-negative minor &lt;i&gt;BCR::ABL1&lt;/i&gt; at 15 months after transplantation.</li>
</ul>
<p></p>
<hr>
<p></p>
<h2>Evidenze per domande cliniche</h2>
<p></p>
<h3>Altro (2)</h3>
<p></p>
<p>#### The Care and Cure of the Leukemias in 2026.</p>
<ul>
<li>Impact score: 1 | Tipo: Preclinico / laboratorio</li>
<li>PMID: 41761287 | 10.1002/ajh.70247</li>
<li>Link PubMed: <a href="https://pubmed.ncbi.nlm.nih.gov/41761287/" target="_blank">https://pubmed.ncbi.nlm.nih.gov/41761287/</a></li>
<li>Open Access (Europe PMC/PMC): non rilevato</li>
</ul>
<p></p>
<p><b>Mini-riassunto (da abstract, estrattivo):</b></p>
<ul>
<li>Tipo di studio/popolazione: Currently, most leukemias are effectively treated with immunotherapies (highly effective monoclonal antibodies targeting CD19 [blinatumomab], or CD22 [inotuzumab ozogamicin]), BCR::ABL1 tyrosine kinase inhibitors (TKIs; e.g., dasatinib, ponatinib), Bruton TKIs (e.g., ibrutinib, acalabrutinib), BCL-2 inhibitors (venetoclax), IDH1/2 inhibitors (ivosidenib, olutasidenib, and enasidenib), FLT3 inhibitors (e.g., midostaurin, quizartinib, and gilteritinib), menin inhibitors (revumenib, ziftomenib), and chimeric antigen receptor T-cell therapies.</li>
<li>Risultato chiave: The BCR::ABL1 TKIs resulted in normal life expectancy in chronic myeloid leukemia.</li>
<li>Rilevanza clinica: Notable advances have also been made in AML with targeted therapies, although some subsets (older/unfit patients for intensive chemotherapy, complex karyotype, TP53-mutated, KMT2A-rearranged, and treated secondary AML) still have unfavorable outcomes.</li>
</ul>
<p></p>
<hr>
<p></p>
<p>#### Secondary Chronic Myeloid Leukemia in the Blast Phase With Mixed Phenotype After Radiation Therapy: A Case Report.</p>
<ul>
<li>Impact score: 1 | Tipo: Preclinico / laboratorio</li>
<li>PMID: 41737783 | 10.1002/jha2.70249</li>
<li>Link PubMed: <a href="https://pubmed.ncbi.nlm.nih.gov/41737783/" target="_blank">https://pubmed.ncbi.nlm.nih.gov/41737783/</a></li>
<li>Open Access (Europe PMC/PMC): sì (PMC12928080)</li>
</ul>
<p></p>
<p><b>Mini-riassunto (da abstract, estrattivo):</b></p>
<ul>
<li>Tipo di studio/popolazione: A 55-year-old woman underwent hysterectomy and pelvic radiation for cervical cancer, which remains in remission.</li>
<li>Risultato chiave: Following induction therapy, sequential therapy with blinatumomab and ponatinib achieved qualitatively PCR-negative minor &lt;i&gt;BCR::ABL1&lt;/i&gt; transcripts, indicating that residual transcripts below the qualitative assay&#x27;s detection limit were undetectable.</li>
<li>Rilevanza clinica: She received an allogeneic bone marrow transplant and remains well with PCR-negative minor &lt;i&gt;BCR::ABL1&lt;/i&gt; at 15 months after transplantation.</li>
</ul>
<p></p>
<p><b>Riassunto aggiuntivo (full text Open Access, estrattivo):</b></p>
<ul>
<li>Metodi (full text OA): non riportato.</li>
<li>Risultato principale (full text OA): non riportato.</li>
<li>Dettaglio utile (full text OA): non riportato.</li>
<li>Messaggio clinico (full text OA): One study indicated that the standardized incidence ratio of CML is not increased in patients who receive radiation therapy alone for cervical cancer [18].</li>
</ul>
<p></p>
<hr>
<p></p>
<h3>Resistenza / T315I / mutazioni (2)</h3>
<p></p>
<p>#### Is asciminib an effective tyrosine kinase inhibitor for chronic myeloid leukemia patients with tyrosine kinase inhibitor resistance?</p>
<ul>
<li>Impact score: 12 | Tipo: Trial clinico</li>
<li>PMID: 41724089 | 10.1016/j.htct.2026.106257</li>
<li>Link PubMed: <a href="https://pubmed.ncbi.nlm.nih.gov/41724089/" target="_blank">https://pubmed.ncbi.nlm.nih.gov/41724089/</a></li>
<li>Open Access (Europe PMC/PMC): sì (PMC12936483)</li>
</ul>
<p></p>
<p><b>Mini-riassunto (da abstract, estrattivo):</b></p>
<ul>
<li>Tipo di studio/popolazione: Such a selective inhibitor offers an alternative treatment strategy for patients with chronic myeloid leukemia who have developed resistance to previous tyrosine kinase inhibitor therapies.</li>
<li>Risultato chiave: Although asciminib demonstrates a superior safety profile, primarily characterized by a reduction in cardiovascular adverse events associated with prior tyrosine kinase inhibitors, its clinical significance extends further.</li>
<li>Rilevanza clinica: It remains essential to continue research and clinical trials to enhance the therapeutic efficacy of asciminib and manage its associated side effects.</li>
</ul>
<p></p>
<p><b>Riassunto aggiuntivo (full text Open Access, estrattivo):</b></p>
<ul>
<li>Metodi (full text OA): non riportato.</li>
<li>Risultato principale (full text OA): non riportato.</li>
<li>Dettaglio utile (full text OA): non riportato.</li>
<li>Messaggio clinico (full text OA): A primary advantage of asciminib is its ability to circumvent the resistance and adverse events associated with traditional TKIs, particularly in patients with advanced-stage CML.</li>
</ul>
<p></p>
<hr>
<p></p>
<p>#### Dual Proteasome and Histone Deacetylase Inhibition Overcomes Tyrosine Kinase Inhibitor Resistance in Breakpoint Cluster Region: Abelson 1-Driven Leukaemia Cell Lines.</p>
<ul>
<li>Impact score: 5 | Tipo: Preclinico / laboratorio</li>
<li>PMID: 41696976 | 10.1111/jcmm.71053</li>
<li>Link PubMed: <a href="https://pubmed.ncbi.nlm.nih.gov/41696976/" target="_blank">https://pubmed.ncbi.nlm.nih.gov/41696976/</a></li>
<li>Open Access (Europe PMC/PMC): sì (PMC12908417)</li>
</ul>
<p></p>
<p><b>Mini-riassunto (da abstract, estrattivo):</b></p>
<ul>
<li>Tipo di studio/popolazione: Resistance to tyrosine kinase inhibitors (TKIs) remains a major challenge in breakpoint cluster region (BCR)::Abelson 1 (ABL1)-driven leukaemias.</li>
<li>Risultato chiave: Viability, cytotoxicity, and caspase-3/7 activity were assessed following single-agent treatment with asciminib, ponatinib, bortezomib, or panobinostat.</li>
<li>Rilevanza clinica: Asciminib showed reduced potency in resistant models and a right-shifted dose-response curve in T315I cells, whereas ponatinib retained activity across BCR::ABL1 variants.</li>
</ul>
<p></p>
<p><b>Riassunto aggiuntivo (full text Open Access, estrattivo):</b></p>
<ul>
<li>Metodi (full text OA): For single‐agent dose–response experiments, cells were treated with 10‐fold serial dilutions ranging from 0 to 1 μM for asciminib and ponatinib and from 0 to 100 nM for bortezomib and panobinostat.</li>
<li>Risultato principale (full text OA): Asciminib is a STAMP inhibitor approved for CML [18].</li>
<li>Dettaglio utile (full text OA): (A) CML cell lines (K562, K562 PR, K562 IR, Ba/F3 asc‐R, Ba/F3 PR, Ba/F3 BCR::ABL, and Ba/F3 T315I) were exposed to asciminib (0–1 μM) for 72 h, and cell viability was measured using the Cell Counting Kit‐8 (CCK‐8) assay.</li>
<li>Messaggio clinico (full text OA): A prior clinical trial explored the combination of a proteasome inhibitor with an HDAC inhibitor in a phase I dose‐escalation study involving belinostat and bortezomib in adult patients with acute leukaemia, myelodysplastic syndromes, or blast‐crisis CML [27].</li>
</ul>
<p></p>
<hr>
<p></p>
<h3>Safety e comorbidità (1)</h3>
<p></p>
<p>#### Is asciminib an effective tyrosine kinase inhibitor for chronic myeloid leukemia patients with tyrosine kinase inhibitor resistance?</p>
<ul>
<li>Impact score: 12 | Tipo: Trial clinico</li>
<li>PMID: 41724089 | 10.1016/j.htct.2026.106257</li>
<li>Link PubMed: <a href="https://pubmed.ncbi.nlm.nih.gov/41724089/" target="_blank">https://pubmed.ncbi.nlm.nih.gov/41724089/</a></li>
<li>Open Access (Europe PMC/PMC): sì (PMC12936483)</li>
</ul>
<p></p>
<p><b>Mini-riassunto (da abstract, estrattivo):</b></p>
<ul>
<li>Tipo di studio/popolazione: Such a selective inhibitor offers an alternative treatment strategy for patients with chronic myeloid leukemia who have developed resistance to previous tyrosine kinase inhibitor therapies.</li>
<li>Risultato chiave: Although asciminib demonstrates a superior safety profile, primarily characterized by a reduction in cardiovascular adverse events associated with prior tyrosine kinase inhibitors, its clinical significance extends further.</li>
<li>Rilevanza clinica: It remains essential to continue research and clinical trials to enhance the therapeutic efficacy of asciminib and manage its associated side effects.</li>
</ul>
<p></p>
<p><b>Riassunto aggiuntivo (full text Open Access, estrattivo):</b></p>
<ul>
<li>Metodi (full text OA): non riportato.</li>
<li>Risultato principale (full text OA): non riportato.</li>
<li>Dettaglio utile (full text OA): non riportato.</li>
<li>Messaggio clinico (full text OA): A primary advantage of asciminib is its ability to circumvent the resistance and adverse events associated with traditional TKIs, particularly in patients with advanced-stage CML.</li>
</ul>
<p></p>
<hr>
<p></p>
<h3>Dose strategy / consolidamento (1)</h3>
<p></p>
<p>#### Dual Proteasome and Histone Deacetylase Inhibition Overcomes Tyrosine Kinase Inhibitor Resistance in Breakpoint Cluster Region: Abelson 1-Driven Leukaemia Cell Lines.</p>
<ul>
<li>Impact score: 5 | Tipo: Preclinico / laboratorio</li>
<li>PMID: 41696976 | 10.1111/jcmm.71053</li>
<li>Link PubMed: <a href="https://pubmed.ncbi.nlm.nih.gov/41696976/" target="_blank">https://pubmed.ncbi.nlm.nih.gov/41696976/</a></li>
<li>Open Access (Europe PMC/PMC): sì (PMC12908417)</li>
</ul>
<p></p>
<p><b>Mini-riassunto (da abstract, estrattivo):</b></p>
<ul>
<li>Tipo di studio/popolazione: Resistance to tyrosine kinase inhibitors (TKIs) remains a major challenge in breakpoint cluster region (BCR)::Abelson 1 (ABL1)-driven leukaemias.</li>
<li>Risultato chiave: Viability, cytotoxicity, and caspase-3/7 activity were assessed following single-agent treatment with asciminib, ponatinib, bortezomib, or panobinostat.</li>
<li>Rilevanza clinica: Asciminib showed reduced potency in resistant models and a right-shifted dose-response curve in T315I cells, whereas ponatinib retained activity across BCR::ABL1 variants.</li>
</ul>
<p></p>
<p><b>Riassunto aggiuntivo (full text Open Access, estrattivo):</b></p>
<ul>
<li>Metodi (full text OA): For single‐agent dose–response experiments, cells were treated with 10‐fold serial dilutions ranging from 0 to 1 μM for asciminib and ponatinib and from 0 to 100 nM for bortezomib and panobinostat.</li>
<li>Risultato principale (full text OA): Asciminib is a STAMP inhibitor approved for CML [18].</li>
<li>Dettaglio utile (full text OA): (A) CML cell lines (K562, K562 PR, K562 IR, Ba/F3 asc‐R, Ba/F3 PR, Ba/F3 BCR::ABL, and Ba/F3 T315I) were exposed to asciminib (0–1 μM) for 72 h, and cell viability was measured using the Cell Counting Kit‐8 (CCK‐8) assay.</li>
<li>Messaggio clinico (full text OA): A prior clinical trial explored the combination of a proteasome inhibitor with an HDAC inhibitor in a phase I dose‐escalation study involving belinostat and bortezomib in adult patients with acute leukaemia, myelodysplastic syndromes, or blast‐crisis CML [27].</li>
</ul>
<p></p>
<hr>
</body>
</html>
